TABLE 3.
Patient EGFR Mutations and Associated Clinical Outcome
| Patient |
EGFR Exon Mutation |
Altered Nucleotide | Altered Amino Acid | Patient History of Resistance to EGFR TKI |
Best Response |
8-Week DCR |
PFS (mo) |
OS (mo) |
|---|---|---|---|---|---|---|---|---|
| 1 | E21 | CTG858CGG | Leu858Arg | Yes | SD | Yes | 6.1 | 20.4 |
| 2 | E21 | CTG858CGG | Leu858Arg | Yes | SD | Yes | 5.7 | 38.5 |
| 3 | E19/E20 | del15bp (746E-750A) /ACG790ATG | del746Glu750Ala/Thr790Met | Yes | SD | Yes | 3.8 | 5.5 |
| 4 | E19 | del15bp (746E-750A) | del746Glu-750Ala | Yes | PD | No | 0.9 | 1.2 |
| 5 | E19/E20 | del15bp (746E-750A) /TGC797TAC | del746Glu-750Ala/Cys797Tyr | No | PD | No | 0.9 | 1.0 |
| 6 | E20 | CAC773CGC | His773Arg | Yes | PR | Yes | 7.4 | 7.4 |
| 7 | E20/E21 | ACG790ATG/CTG858CGG | Thr790Met/Leu858Arg | Yes | PD | No | 1.9 | 4.1 |
| 8 | E20/E21 | GTC802ATC/AAG852AGG | Val802Ile/Lys852Arg | Yes | SD | Yes | 2.6 | 6.3 |
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; DCR, disease control rate; PFS, progression-free survival; OS, overall survival.